Research Article
Safety and Efficacy of Intrapleural Tissue Plasminogen Activator and DNase during Extended Use in Complicated Pleural Space Infections
Table 2
Outcomes of patients receiving intrapleural therapy.
| | Standard IPFT | Extended IPFT | value |
| Patients () | 81 | 20 | | Total number of chest tubes [median [interquartile range (25–75)]] | 1 1-1 | 2 1-2 | 0.015 | Placement of additional chest tube after IPFT initiation ( (%)) | 12 (15) | 7 (35) | 0.080 | Median outcomes in hospital days [interquartile range (25–75)] | | | | Chest tube duration | 6 4–11 | 8 6–11 | 0.200 | Hospital length of stay | 13 9–19 | 17 9–25 | 0.355 | Admission to lytic cessation | 7 5–11 | 9 5–12 | 0.281 | Admission to surgery day | 6 0–14 | 7 7–14 | 0.975 | Day of surgery to discharge | 11 6–21 | 16 11–22 | 0.534 | Lytic cessation to discharge | 4 3–9 | 3 1–19 | 0.404 | Referral for surgery ( (%)) | 13 (16) | 3 (15) | 0.821 | Complications (, (%)) | | | | Readmission | 13 (16) | 2 (10) | 0.741 | Outpatient pleural drainage | 10 (12) | 2 (10) | 0.924 | Bleeding | 2 (3) | 2 (10) | 0.365 | Tube dislodgement | 3 (4) | 3 (15) | 0.166 | New narcotic use | 46 (57) | 16 (80) | 0.056 |
|
|